Ondine issues milestone shares after completing first ICU Steriwave trial

Ondine Biomedical, Inc. ( (GB:OBI) ) just unveiled an announcement.

Ondine Biomedical will issue 1,184,504 new common shares to the Royal Columbian Hospital Foundation’s Advancing Innovation in Medicine division after achieving the final milestone in an ICU pilot study of its Steriwave nasal photodisinfection system. The milestone was triggered by submission of the study results for publication, marking completion of the world’s first ICU-based clinical trial of this non-resistance-forming technology and advancing Ondine’s push into critical care settings.

The equity-based payment, priced at 9.75 pence per share and representing 25% of the C$855,000 pilot study cost, allows Ondine to preserve cash while deepening clinical partnerships that expand the evidence base for Steriwave in an estimated C$4 billion ICU market. Following admission of the new shares to trading on AIM, expected around 27 February 2026, Ondine’s issued share capital will rise to 519,551,468 common shares, slightly diluting existing shareholders but reinforcing the company’s strategic positioning in hospital infection control and critical care.

The most recent analyst rating on (GB:OBI) stock is a Sell with a £8.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.

Spark’s Take on GB:OBI Stock

According to Spark, TipRanks’ AI Analyst, GB:OBI is a Underperform.

Ondine Biomedical, Inc. receives a low overall score due to significant financial performance challenges, bearish technical indicators, and unattractive valuation metrics. The company’s strong revenue growth is overshadowed by its inability to achieve profitability and positive cash flow, while technical analysis suggests continued negative momentum.

To see Spark’s full report on GB:OBI stock, click here.

More about Ondine Biomedical, Inc.

Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, to prevent and treat infections, including those caused by multidrug-resistant organisms. Its flagship Steriwave nasal photodisinfection system is approved for nasal decolonisation in multiple countries, holds a CE mark in Europe, has U.S. FDA Fast Track and Qualified Infectious Disease Product designations, and is supported by a pipeline targeting indications such as chronic sinusitis, ventilator-associated pneumonia and burns.

Average Trading Volume: 215,300

Technical Sentiment Signal: Sell

Current Market Cap: £51.84M

For detailed information about OBI stock, go to TipRanks’ Stock Analysis page.